A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab) at its second attempt, having been turned down by the US regulator last year. The tissue ...

As we commence 2025, for those who are considered leaders or visionaries in their fields, it’s time to dust off the crystal ball and make some bold predictions about what this year will bring.

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...